生命科学资讯

Moderna to pay up to $2.25B to end mRNA vaccine patent fight

Blackstone puts $400M into Teva, Sanofi gut disease drug

Prime to test FDA flexibility with 2-patient gene editing submission

FDA again targets GLP-1 compounders; Intellia to restart heart disease trial

Kyowa Kirin abandons touted eczema drug following safety review

Pierre Fabre seeks to revive US approval chances for spurned cell therapy

Ascendis wins FDA approval of dwarfism drug

UniQure says FDA wants another study of Huntington’s gene therapy

Roche pill succeeds in another MS study, but approval questions linger

Candid, in a reverse merger with RallyBio, to go public

Safety concerns spur Aardvark to halt key Prader-Willi drug trial

Why it’s critical to close open steps in cell therapy manufacturing

Atrium spins out of Avidity, aiming to target rare heart diseases with RNA

UniQure falls further on Makary comments

Moderna’s combination flu, COVID shot wins over European drug regulators

Generate caps a strong month for biotech IPOs with $400M offering

Lilly’s GLP-1 pill tops Novo’s Rybelsus in head-to-head trial

Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer

Boehringer drug approved in 44 days; BioMarin shelves Roctavian

Sarepta CEO Doug Ingram to retire, with company at a crossroads